Essential Medicines Clause Samples

Essential Medicines. The unions and employees recognise the Company’s obligation to assemble and distribute life saving ethical, hospital and pharmacy only products at all times. The union and employees agree not to disrupt, interfere with or stop receipt, assembly and distribution of ethical, hospital and pharmacy only products at any time.
View SourceView Similar (4)
Essential Medicines. The union and employees recognise the Company’s obligation to assemble and distribute life saving ethical, hospital products and equipment, and pharmacy-only products and equipment at all times. The union and employees agree not to stop, disrupt, or otherwise interfere with the receipt, assembly and distribution of ethical, hospital products and equipment, and pharmacy-only products and equipment at any time. Without limiting the generality of the clause above, on the basis of present ▇▇▇▇▇▇▇ levels, a minimum of thirty-seven experienced employees (union and/ or non-union members) are necessary to ensure the assembly of prescription and medical items. To facilitate the implementation of this clause, sufficient staff will need to be maintained to operate Receiving, Order Induction, DD/ Fridges, A-Frame, CLS, Binning, 3PL, Lidding, Despatch, Invoice Production, Transport.
View SourceView Similar (2)
Essential Medicines. In order to ascertain the requirements from all sources per annum, a review of the current government allocation, estimated individual revenue from RDF sales was conducted and compared to the forecasted need in the National Health Sector Strategic Plan 2022-2026 to determine if there is any funding limitation for essential Medicines. The table 12 below provides a summary of the funding analysis; Essential Medicines and Commodities US$ 41.2 million US$3.8 million US$ 7.2 million US$30.2 million Per Capita Requirements US$7.9 US$0.7 US$ 1.4 US$5.8 An examination of the fiscal landscape reveals a concerning trend in government allocations towards the procurement of essential medicines. Presently, government apportions a modest US$3.8 million, which equates to a mere 9% of the estimated annual requirement of US$41.2 million. This glaring discrepancy underscores the limited fiscal space and poses substantial challenges in realizing comprehensive and effective healthcare provisioning. The proposed Revolving Drug Fund (RDF) offers a notable avenue for augmenting available resources. With an estimated annual revenue of US$7.2 million, the RDF holds the potential to contribute significantly to the financial requirements for essential medicines provision. However, it is essential to temper this potential with realism. While substantial, this revenue stream would constitute only 17% of the estimated requisite resources per annum, exposing the substantial resource gap that looms large. The pronounced resource gap of US$30.2 million per annum presents a ▇▇▇▇▇ reality, necessitating external support to bridge this glaring deficit. The pivotal role of donors becomes palpable in this context, as their substantial contribution becomes imperative to achieve the national health system's ability to meet essential medicine requirements. Moreover, it is paramount to acknowledge the prerequisite of seed capital amounting to US$25.9 million to establish the national RDF model. This additional fiscal demand, when compared against the already existing resource gap, compounds the challenge in achieving the aspirational goal of Universal Health Coverage (UHC). Cost-sharing Model and Resource Requirements from Sources‌ In order to ascertain the requirements from all sources per annum for service provision without drugs, a review of the current government allocation to Counties for FY2023, estimated individual revenue from Scenario 1 of the Cost sharing Model was compared to the Calcula...
View Source
Essential Medicines. If a company plans to halt production or sale of one of its proprietary products which satisfies a particular medical need that would no longer be fulfilled if the product were removed from the market, the company undertakes to enter into discussions with CEPS regarding the financial situation involved in keeping the product on the market, failing which the company's status as an approved supplier may be removed. If a company requests a price increase for one of its proprietary products that satisfies a medical need not catered for by any other less expensive medicine and the price increase is justified in view of the financial circumstances surrounding the production of the medicine, when evaluating the request account shall be taken of obligations arising from tests on traces of the medicine in water and of the specific cost of the collection and disposal of sharps waste from patients self medicating with the product. Section II: Sources of savings Article 13: Development of generics and fixed accountability tariffs (tarifs forfaitaires de responsabilité – TFRs)
View Source
Essential Medicines. The UWU and Employees recognise the Employer's obligation to comply with requirements under the Federal Government's Community Service Obligation (CSO) Deed. This Deed covers all PBS medicines and requires no disruption to the distribution of these medicines. The UWU and Employees agree not to disrupt, interfere with or stop receipt, assembly and distribution of medicines covered under the CSO Deed of Arrangement.
View Source
Essential Medicines. The employees recognise the Employer's obligation to comply with requirements under the Federal Government's Community Service Obligation (CSO) Deed. This Deed covers all PBS products and requires that there is no disruption to the distribution of these medicines. The employees agree not to disrupt, interfere with or stop receipt, assembly and/or distribution of medicines covered under the CSO Deed of Arrangement.
View Source
Essential Medicines. The union and employees recognize the Company’s obligation to manufacture, package and distribute life saving essential medicines and pharmacy only products at all times. The union and employees agree not to disrupt, interfere with or stop receipt, manufacture, testing and distribution of essential medicines and pharmacy only products at any time and commit to ensuring minimum levels of experienced employees are maintained during the manufacturing process to meet this objective. The term "experienced employees" means employees with substantial experience in the manufacture, testing, packaging or dispatch of products.
View Source
Essential Medicines. The Union and Employees recognise the Employer’s obligation to assemble and distribute lifesaving ethical, hospital products and equipment, and pharmacy-only products and equipment at all times. The Union and Employees agree not to stop, disrupt, or otherwise interfere with the receipt, assembly and distribution of those products and equipment at any time.
View Source

Related to Essential Medicines

  • Essential Services For purposes of service restoral, Embarq shall designate a CLEC access line as an Essential Service Line (ESL) at Parity with Embarq’s treatment of its own end users and applicable state law or regulation, if any.

  • Surgery Services This plan covers surgery services to treat a disease or injury when: • the operation is not experimental or investigational, or cosmetic in nature; • the operation is being performed at the appropriate place of service; and • the physician is licensed to perform the surgery. This plan covers reconstructive surgery and procedures when the services are performed to relieve pain, or to correct or improve bodily function that is impaired as a result of: • a birth defect; • an accidental injury; • a disease; or • a previous covered surgical procedure. Functional indications for surgical correction do not include psychological, psychiatric or emotional reasons. This plan covers the procedures listed below to treat functional impairments. • abdominal wall surgery including panniculectomy (other than an abdominoplasty); • blepharoplasty and ptosis repair; • gastric bypass or gastric banding; • nasal reconstruction and septorhinoplasty; • orthognathic surgery including mandibular and maxillary osteotomy; • reduction mammoplasty; • removal of breast implants; • removal or treatment of proliferative vascular lesions and hemangiomas; • treatment of varicose veins; or • gynecomastia.

  • Telemedicine Services This plan covers clinically appropriate telemedicine services when the service is provided via remote access through an on-line service or other interactive audio and video telecommunications system in accordance with R.I. General Law § 27-81-1. Clinically appropriate telemedicine services may be obtained from a network provider, and from our designated telemedicine service provider. When you seek telemedicine services from our designated telemedicine service provider, the amount you pay is listed in the Summary of Medical Benefits. When you receive a covered healthcare service from a network provider via remote access, the amount you pay depends on the covered healthcare service you receive, as indicated in the Summary of Medical Benefits. For information about telemedicine services, our designated telemedicine service provider, and how to access telemedicine services, please visit our website or contact our Customer Service Department.

  • Diagnostic Services Procedures ordered by a recognized Provider because of specific symptoms to diagnose a specific condition or disease. Some examples include, but are not limited to:

  • Radiation Therapy/Chemotherapy Services This plan covers chemotherapy and radiation services. This plan covers respiratory therapy services. When respiratory services are provided in your home, as part of a home care program, durable medical equipment, supplies, and oxygen are covered as a durable medical equipment service.